EFFICACY AND SAFETY OF A TARGETED-RELEASE FORMULATION OF BUDESONIDE (HR19042 CAPSULES) IN PATIENTS WITH PRIMARY IGA NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2/3 TRIAL